Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Claims Sole Authority Over Naming Of US-Licensed Biologics

Feb 03 2017

• By Sue Sutter

Related Content

GPhA Resorts To Citizen Petition On Biosimilar Naming

Sep 20 2013

The Curious Case Of FDA, <em>Zarxio</em>’s Name And The USP Monograph

Mar 23 2015

Track-And-Trace Insufficient For Biosimilar Pharmacovigilance, Brand Companies Say

Jan 09 2014

Sandoz Tells FDA Unique Biosimilar Names OK… Sometimes

May 11 2015

FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach

Aug 27 2015

Biosimilar Name Debate Heats Up As USP Says <em>Zarxio</em> Doesn't Need Suffix

Jan 25 2016

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Jan 13 2017

Biological Product Suffix Submissions Limited To 10 Candidates By US FDA

Jan 16 2017

Related Companies

Novartis AG

Johnson & Johnson

Novartis AG

Amgen, Inc.

Additional Topics

Biosimilars Biologics Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window